Earlier Detection, Better Outcomes in Ovarian Cancer | Diagnostic Gaps

Ovarian cancer remains one of the deadliest gynecologic malignancies, largely because approximately 75% of cases are diagnosed at an advanced stage. A critical lack of reliable population-level screening methods, combined with highly nonspecific symptoms, makes early detection one of the greatest unmet needs in gynecologic oncology. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/earlier-detection-better-outcomes-ovarian-cancer In this discussion, experts join Dr. Jasmin Hundal to explore the ongoing challenges of early diagnosis. They review recent therapeutic breakthroughs for platinum-resistant disease—including newly approved antibody-drug conjugates (ADCs) and novel immunotherapy combinations—and highlight the promise of precision medicine and investigational agents like KAD101 in bridging the diagnostic and therapeutic gaps. What You’ll Learn in This Episode: 🔹 The Dilemma of Delayed Diagnosis: Understanding why the anatomical location and nonspecific symptoms of ovarian cancer lead to three-quarters of patients presenting with advanced, metastatic disease. 🔹 Limitations of Current Diagnostics: Analyzing the clinical constraints of transvaginal ultrasound and serum CA-125 testing, and why they fail as reliable population-based screening tools. 🔹 Expanding Options in Platinum-Resistant Disease: Reviewing newly approved therapies, including mirvetuximab soravtansine (folate receptor alpha ADC), pembrolizumab plus paclitaxel, and relacorilant plus nab-paclitaxel. 🔹Targeting the Prolactin Receptor: Discussing the biological rationale and clinical pipeline for KAD101, an investigational antagonist targeting the prolactin pathway in recurrent ovarian cancer. 🔹 The Role of Genomic Screening: Evaluating how rapid, cost-effective genomic sequencing and homologous recombination deficiency (HRD) status guide personalized treatment and PARP inhibitor selection.